Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Ji, Guiyuan ^a   Zhao, Xihong ^b   Leng, Liang ^a   Liu, Peiyi ^a   Jiang, Zhuoqin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b WUHAN INSTITUTE OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMINOTRANSFERASE; ATORVASTATIN; LIPID; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRROLE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; GENE EXPRESSION; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; LIPID BLOOD LEVEL; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER FUNCTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DIET THERAPY; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MULTIMODALITY CANCER THERAPY; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; COMBINED MODALITY THERAPY; DIETARY FATS; FATTY LIVER; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPIDS; LIVER; MALE; ORGAN SIZE; PPAR ALPHA; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSAMINASES;

EID: 79251560927     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-23     Document Type: Article

References (30)

1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
2. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl 1):S5-10.
3. Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50:204-210.
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
5. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K: Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009, 44(Suppl 19):89-95.
6. Kashi MR, Torres DM, Harrison SA: Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:396-406.
7. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R: A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647. (Pubitemid 43727474)
8. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K: Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 45:750-757.
9. Liang K, Vaziri ND: HMG-CoA reductase, cholesterol 7 alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia. Kidney Int 2003, 64:192-198. (Pubitemid 36714171)
10. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967. (Pubitemid 36733754)
11. Botezelli JD, Mora RF, Dalia RA, Moura LP, Cambri LT, Ghezzi AC, Voltarelli FA, Mello MA: Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis 2010, 9:116.
12. Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, Ushirogawa M, Tsuzura T, Nakashita S, Takahashi H, et al: A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009, 44:1203-1208.
13. Zhang X, Yang J, Guo Y, Ye H, Yu C, Xu C, Xu L, Wu S, Sun W, Wei H, et al: Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010, 51:1190-1199.
14. Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K: Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007, 22:2009-2014. (Pubitemid 47525065)
15. Janes RG, Prosser M: Influence of high fat diets on alloxan diabetes. Am J Physiol 1947, 151:581-587.
16. Tuomisto JT, Pohjanvirta R, Unkila M, Tuomisto J: TCDD-induced anorexia and wasting syndrome in rats: effects of diet-induced obesity and nutrition. Pharmacol Biochem Behav 1999, 62:735-742. (Pubitemid 29127179)
17. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P: Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128. (Pubitemid 351975537)
18. Martin-Castillo A, Castells MT, Adanez G, Polo MT, Perez BG, Ayala I: Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. Biomed Pharmacother 64:275-281.
19. Begriche K, Igoudjil A, Pessayre D, Fromenty B: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
20. Ahmed MH, Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007, 12:740-747.
21. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, et al: PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008, 23:102-109. (Pubitemid 350265194)
22. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T: Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006, 26:613-620.
23. Sanguino E, Roglans N, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC: Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 2005, 145:853-861. (Pubitemid 41129006)
24. Roglans N, Sanguino E, Peris C, Alegret M, Vazquez M, Adzet T, Diaz C, Hernandez G, Laguna JC, Sanchez RM: Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002, 302:232-239. (Pubitemid 34680443)
25. Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA: Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 2003, 11:25-33. (Pubitemid 36126588)
26. Roitelman J, Olender EH, Bar-Nun S, Dunn WA Jr, Simoni RD: Immunological evidence for eight spans in the membrane domain of 3- hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. J Cell Biol 1992, 117:959-973.
27. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
28. Ringseis R, Muschick A, Eder K: Dietary oxidized fat prevents ethanol-induced triacylglycerol accumulation and increases expression of PPARalpha target genes in rat liver. J Nutr 2007, 137:77-83. (Pubitemid 46052862)
29. Salas A, Noe V, Ciudad CJ, Romero MM, Remesar X, Esteve M: Short-term oleoyl-estrone treatment affects capacity to manage lipids in rat adipose tissue. BMC Genomics 2007, 8:292.
30. Uno M, Kurita S, Misu H, Ando H, Ota T, Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, et al: Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 2008, 48:109-118. (Pubitemid 351975536)